Device Trial Radar · NCT06406439
DIA:CONN P8(Smart Insulin Pen) Study in Diabetes Patients
Last checked: Nov 19, 2026Latest source record: Aug 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
120
Actual
Start
May 21, 2024
Primary completion
Apr 2, 2025
Study completion Apr 2, 2025
Sponsor
- Lead sponsor
- G2e Co., LtdNot on our public-company list
- Sponsor type
- Industry
- First posted
- May 9, 2024
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 19 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Multicenter, Open label, Randomized, Comparative Study to Evaluate the Efficacy and Safety of Electric Smart Insulin Pen DIA:CONN P8 in patients with Type 1, Type 2 or Pancreatogenic Diabetes Mellitus under Multiple Dose Insulin Therapy
Conditions
- Diabetes (Insulin-requiring, Type 1 or Type 2)
- Pancreatogenic Diabetes Mellitus
Interventions
Smart Insulin PenDevice
During the 12-week, for basal insulin, the treatment group will input and inject the dosage using the DIA:CONN P8, using only the insulin injection and injection recording functions, same as the blind CGM period. For bolus insulin, when the carbohydrate counting is entered or the type of meal is selected into the DIA:CONN P8 application, the insulin dosage is automatically calculated and set using the entered information and other indicators. Subjects inject the insulin at that calculated dosage using the DIA:CONN P8.
Injection of bolus insulin via conventional therapy using insulin penDevice
During the 12-week, the control group will use DIA:CONN P8 to manually input and inject the dosage of both basal and bolus insulin, only using the insulin injection and injection recording functions, same as the blind CGM period.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in HbA1c(%) at 12 weeks compared to baselineTime frame: from baseline to the 12-week time point
Locations
9 sites in 1 country. Site status is shown where the registry gives one.
Chung-Ang University Gwangmyeong Hospital
Gwangmyeong, Deokan-ro, South Korea
Kyung Hee University Hospital
Seoul, Dongdaemun-gu, South Korea
Kyung Hee University Hospital at Gangdong
Seoul, Gangdong-gu, South Korea
6 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.